Skip to main content
INVAMED
HomeINVAblogVenous Thromboembolism in Cancer Patients: Risk Assessment, Prevention, and Management
MedicalMarch 1, 2026INVAMED Medical Affairs

Venous Thromboembolism in Cancer Patients: Risk Assessment, Prevention, and Management

Cancer substantially increases the risk of venous thromboembolism. Risk-adapted prophylaxis and individualized anticoagulation are central to management in oncology.

Venous thromboembolism (VTE) — deep vein thrombosis and pulmonary embolism — is a leading complication and cause of death in patients with cancer. The malignancy itself, its treatments, and patient factors combine to create a prothrombotic state that requires deliberate risk assessment and management.

Why cancer raises VTE risk

Tumors can activate coagulation directly and through inflammation; chemotherapy, hormonal therapy, and anti-angiogenic agents add further risk; and central venous catheters, surgery, and immobility compound it. Risk varies markedly by cancer type, stage, and treatment phase.

Risk assessment

Validated risk scores help identify ambulatory patients most likely to benefit from prophylaxis, incorporating cancer site, blood counts, and body-mass index. Risk is dynamic and should be reassessed at transitions such as hospitalization, surgery, and new therapy.

Prevention

  • Hospitalized patients generally receive pharmacologic prophylaxis unless contraindicated.
  • Surgical oncology patients benefit from extended postoperative prophylaxis for major abdominal-pelvic procedures.
  • Selected high-risk ambulatory patients may be offered primary prophylaxis based on risk score and bleeding profile.

Management of established VTE

Anticoagulation is the foundation of treatment. Contemporary options include low-molecular-weight heparin and direct oral anticoagulants, with the choice individualized by cancer site (for example, gastrointestinal bleeding risk), drug interactions, renal function, and patient preference. In patients with contraindications to anticoagulation, mechanical approaches and, in selected cases, inferior vena cava filters have a role. Duration is guided by ongoing cancer activity and treatment.

INVAMED technologies in this space

INVAMED's venous portfolio includes thrombectomy platforms and IVC filters; explore the deep vein thrombosis category.

Device availability and approved indications vary by country. This content is prepared for healthcare professionals and does not replace clinical judgment or the instructions for use.

Reviewed by: INVAMED Medical Affairs

This content is prepared for educational purposes for healthcare professionals and does not constitute medical advice. Always consult clinical guidelines and product instructions for use.

venous thromboembolismcancer-associated thrombosisDVTanticoagulation